
-
Neurocrine Biosciences NASDAQ:NBIX Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems.
Location: 12780 El Camino Real, California, 92130-2042, US | Website: www.neurocrine.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
11.45B
Cash
1.076B
Avg Qtr Burn
N/A
Short % of Float
2.44%
Insider Ownership
1.87%
Institutional Own.
97.79%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
INGREZZA (valbenazine) Details Huntington's disease, Dyskinesia | Approved Quarterly sales | |
INGREZZA (valbenazine) Details Huntington's disease, Chorea | Approved Quarterly sales | |
CRENESSITY™ (crinecerfont) [capsule] Details Congenital adrenal hyperplasia | Approved Quarterly sales | |
CRENESSITY™ (crinecerfont) [oral solution] Details Congenital adrenal hyperplasia | Approved Quarterly sales | |
INGREZZA (valbenazine) Details Chorea, Huntington's disease, Dyskinesia | Approved Quarterly sales | |
Valbenazine Details Neurological disorder, Dyskinesia , Cerebral Palsy | Phase 3 Data readout | |
Valbenazine Details Psychiatric disorder, Schizophrenia | Phase 3 Data readout | |
Osavampator (NBI-1065845/TAK-653) Details Major depressive disorder | Phase 3 Initiation | |
NBI-1117568 Details Schizophrenia | Phase 3 Initiation | |
NBI-1070770 (NMDA NR2B Negative Allosteric Modulator) Details Major depressive disorder | Phase 2 Data readout | |
Chronocort® (Efmody) Details Adrenal Insufficiency | Phase 2 Update | |
NBI-1065846 Details Major depressive disorder | Phase 2 Update | |
Efmody Details Congenital adrenal hyperplasia | Phase 2 Update | |
NBI-921352 Details Focal Onset Seizures | Phase 2 Update | |
NBI-1117567 Details Neurological disorder, Psychiatric disorder | Phase 1 Data readout | |
NBI-1076986 Details Parkinson's disease, Dystonia (Blepharospasm) | Phase 1 Data readout | |
NBI-1117570 (Dual M1/M4 Agonist) Details Schizophrenia | Phase 1 Data readout | |
NBI-1065890 Details Neurological disorder | Phase 1 Data readout | |
Luvadaxistat Details Psychiatric disorder, Schizophrenia | Failed Discontinued |